The Molecular Examiner

Ipamorelin: The Cleanest Selective Ghrelin-Receptor Agonist

A pentapeptide GH-releasing peptide that triggers pulsatile GH release without affecting cortisol or prolactin. The selectivity profile that makes it the canonical reference compound.

The Molecular Examiner Editorial · · 1 min read · 309 words

Ipamorelin is a pentapeptide growth-hormone-releasing peptide (GHRP) — Aib-His-D-2-Nal-D-Phe-Lys-NH₂. Among published GHRPs, ipamorelin has the cleanest selectivity profile for the ghrelin receptor, which is why it’s become the canonical reference compound for GH-axis research.

What makes it “selective”

Earlier GHRPs (GHRP-2, GHRP-6, hexarelin) trigger growth-hormone release but also raise cortisol, prolactin, and ACTH — confounders in pure GH-axis research. Ipamorelin, in published animal and human pharmacological studies:

  • Triggers pulsatile GH release at the magnitude of GHRP-6
  • Does not significantly affect cortisol secretion
  • Does not significantly affect prolactin
  • Does not affect ACTH

For research programs studying GH-axis pharmacology without confounding stress-hormone effects, this selectivity profile is the reason ipamorelin remains the reference compound rather than the broader-acting older GHRPs.

Mechanism

Ipamorelin binds the ghrelin receptor (GHS-R1a) on pituitary somatotrophs and hypothalamic neurons. Ghrelin-receptor activation:

  • Triggers GH release from pituitary somatotrophs
  • Suppresses somatostatin (which normally inhibits GH release) at the hypothalamic level

The combination produces a pulsatile GH release pattern that resembles endogenous secretion more closely than continuous exogenous GH administration.

Half-life

Plasma half-life in humans is approximately 2 hours. GH release peaks within 5-15 minutes of administration and returns to baseline within ~3 hours. The pharmacokinetics support intermittent rather than continuous administration in research protocols.

Research contexts

Ipamorelin has been studied in:

  • GH-axis pharmacology characterization
  • Sarcopenia-related research models
  • Post-surgical recovery models (where GH plays a role)
  • Pediatric GH-deficiency research (clinical trials)

Clinical translation has occurred in some indications but ipamorelin is not approved for general therapeutic use.

Sourcing notes

The pentapeptide is stable in lyophilized form. Purity >98% HPLC is the reference threshold. Reference-grade material should ship with mass-spec confirmation matching theoretical molecular weight (711 Da). The peptide is hygroscopic — store lyophilized at -20°C, reconstitute in bacteriostatic water for the standard 28-day refrigerated window.

Related notes

Continue reading.